David Linetsky Sells 6,106 Shares of Phreesia (NYSE:PHR) Stock

Phreesia, Inc. (NYSE:PHR) insider David Linetsky sold 6,106 shares of the company’s stock in a transaction on Thursday, January 8th. The shares were sold at an average price of $17.01, for a total transaction of $103,863.06. Following the completion of the sale, the insider owned 231,723 shares of the company’s stock, valued at approximately $3,941,608.23. This trade represents a 2.57% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

David Linetsky also recently made the following trade(s):

• On Wednesday, December 17th, David Linetsky sold 94 shares of Phreesia stock. The stock was sold at an average price of $16.49, for a total transaction of $1,550.06.
• On Friday, October 17th, David Linetsky sold 2,059 shares of Phreesia stock. The shares were sold at an average price of $22.36, for a total transaction of $46,039.24.

Phreesia Stock Performance

Shares of NYSE:PHR traded down $0.10 on Monday, reaching $17.14. The company’s stock had a trading volume of 760,277 shares, compared to its average volume of 1,018,096. Phreesia, Inc. has a 52-week low of $15.41 and a 52-week high of $32.76. The stock has a market capitalization of $1.03 billion, a P/E ratio of -171.33 and a beta of 0.61. The stock’s 50-day moving average is $18.95 and its two-hundred day moving average is $23.69. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.44 and a quick ratio of 2.44.

Phreesia (NYSE:PHR) last issued its quarterly earnings results on Monday, December 8th. The company reported $0.10 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.01) by $0.11. The firm had revenue of $120.33 million for the quarter, compared to analysts’ expectations of $119.98 million. Phreesia had a negative return on equity of 1.31% and a negative net margin of 1.16%.The firm’s revenue for the quarter was up 12.7% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.25) EPS. As a group, sell-side analysts forecast that Phreesia, Inc. will post -1.1 EPS for the current year.

Institutional Investors Weigh In On Phreesia

Hedge funds and other institutional investors have recently modified their holdings of the stock. Royal Bank of Canada boosted its stake in shares of Phreesia by 208.8% during the 1st quarter. Royal Bank of Canada now owns 24,119 shares of the company’s stock worth $617,000 after acquiring an additional 16,309 shares in the last quarter. AQR Capital Management LLC raised its holdings in Phreesia by 471.2% during the first quarter. AQR Capital Management LLC now owns 160,032 shares of the company’s stock worth $4,090,000 after purchasing an additional 132,015 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in Phreesia by 3.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 62,557 shares of the company’s stock worth $1,599,000 after purchasing an additional 2,158 shares during the last quarter. NewEdge Advisors LLC boosted its position in Phreesia by 262.7% during the first quarter. NewEdge Advisors LLC now owns 15,437 shares of the company’s stock worth $395,000 after purchasing an additional 11,181 shares in the last quarter. Finally, Goldman Sachs Group Inc. grew its holdings in Phreesia by 0.4% in the first quarter. Goldman Sachs Group Inc. now owns 600,012 shares of the company’s stock valued at $15,336,000 after purchasing an additional 2,402 shares during the last quarter. 92.10% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on PHR. Needham & Company LLC reaffirmed a “buy” rating and set a $35.00 price target on shares of Phreesia in a report on Monday, December 8th. Barclays reduced their target price on shares of Phreesia from $26.00 to $24.00 and set an “overweight” rating for the company in a research note on Tuesday, December 16th. Canaccord Genuity Group lowered their target price on shares of Phreesia from $38.00 to $33.00 and set a “buy” rating on the stock in a report on Tuesday, December 9th. DA Davidson increased their price target on shares of Phreesia from $33.00 to $35.00 and gave the stock a “buy” rating in a report on Tuesday, December 2nd. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Phreesia in a research report on Friday, October 31st. Seventeen research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $30.06.

Phreesia Company Profile

Phreesia, Inc (NYSE: PHR) is a provider of patient intake management solutions designed to streamline front-office workflows for healthcare organizations. The company’s cloud-based platform digitizes patient registration, appointment scheduling, insurance verification, consent documentation and payment collection through touchscreen kiosks, tablets and mobile devices. By replacing paper forms and manual processes, Phreesia enhances data accuracy, reduces administrative burden and improves the patient experience.

Founded in 2000 by Chaim Indig and headquartered in Burlington, Massachusetts, Phreesia offers a modular software suite that integrates with electronic medical record (EMR) and practice management systems.